Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals Share Price (NASDAQ: ARWR)

$21.32

0.57

(2.75%)

Last updated on

Check the interactive Arrowhead Pharmaceuticals Stock chart to analyse performance

Arrowhead Pharmaceuticals stock performance

as on August 23, 2025 at 1:29 AM IST

  • Today's Low:$20.80
    Today's High:$21.69

    Day's Volatility :4.1%

  • 52 Weeks Low:$9.57
    52 Weeks High:$27.34

    52 Weeks Volatility :65.0%

Arrowhead Pharmaceuticals Stock Returns

PeriodArrowhead Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
34.97%
5.1%
0.0%
6 Months
13.12%
-6.4%
0.0%
1 Year
-13.9%
-11.8%
0.0%
3 Years
-50.09%
5.9%
-7.8%

Arrowhead Pharmaceuticals, Inc. Key Stats

Check Arrowhead Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$20.75
Open
$20.83
Today's High
$21.69
Today's Low
$20.8
Market Capitalization
$2.9B
Today's Volume
$2.6M
52 Week High
$27.34
52 Week Low
$9.57
Revenue TTM
$573.0M
EBITDA
$-85.4M
Earnings Per Share (EPS)
$-1.2
Profit Margin
-25.9%
Quarterly Earnings Growth YOY
0.1%
Return On Equity TTM
-37.11%

Stock Returns calculator for Arrowhead Pharmaceuticals Stock including INR - Dollar returns

The Arrowhead Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arrowhead Pharmaceuticals investment value today

Current value as on today

₹90,353

Returns

₹9,647

(-9.65%)

Returns from Arrowhead Pharmaceuticals Stock

₹13,963 (-13.96%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Arrowhead Pharmaceuticals Stock

90%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Arrowhead Pharmaceuticals Stock from India on INDmoney has increased by 90% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Arrowhead Pharmaceuticals, Inc.

  • Name

    Holdings %

  • BlackRock Inc

    14.42%

  • Vanguard Group Inc

    11.24%

  • venBio Select Advisor LLC

    7.67%

  • State Street Corp

    5.07%

  • Slate Path Capital LP

    3.79%

  • FMR Inc

    2.40%

Analyst Recommendation on Arrowhead Pharmaceuticals Stock

Rating
Trend

Buy

    75%Buy

    25%Hold

    0%Sell

Based on 20 Wall street analysts offering stock ratings for Arrowhead Pharmaceuticals(by analysts ranked 0 to 5 stars)

Arrowhead Pharmaceuticals Share Price Target

What analysts predicted

Upside of 105.37%

Target:

$43.79

Current:

$21.32

Arrowhead Pharmaceuticals share price target is $43.79, a slight Upside of 105.37% compared to current price of $21.32 as per analysts' prediction.

Arrowhead Pharmaceuticals Stock Insights

  • Price Movement

    In the last 1 month, ARWR stock has moved up by 30.3%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 542.70M → 27.76M (in $), with an average decrease of 94.9% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 370.44M → -175.24M (in $), with an average decrease of 147.3% per quarter
  • ARWR vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 71.2% return, outperforming this stock by 87.5%
  • ARWR vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 115.2% return, outperforming this stock by 164.9%
  • Price to Sales

    ForARWR every $1 of sales, investors are willing to pay $4.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Arrowhead Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Arrowhead Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Arrowhead Pharmaceuticals, Inc. Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Arrowhead Pharmaceuticals, Inc. logo
31.21%
13.12%
-13.9%
-50.09%
-50.22%
Regeneron Pharmaceuticals, Inc. logo
5.93%
-16.14%
-50.12%
-0.77%
0.56%
Beone Medicines Ltd logo
5.89%
21.45%
61.97%
78.16%
32.24%
Vertex Pharmaceuticals Incorporated logo
-15.86%
-17.5%
-17.43%
36.53%
48.58%
Alnylam Pharmaceuticals, Inc. logo
42.31%
87.51%
71.21%
111.21%
254.29%

Arrowhead Pharmaceuticals Dividend announcements

  • Arrowhead Pharmaceuticals Earnings

    Arrowhead Pharmaceuticals’s price-to-earnings ratio stands at None

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Organization
Arrowhead Pharmaceuticals
Employees
609
CEO
Dr. Christopher R. Anzalone Ph.D.
Industry
Health Technology

Key Management of Arrowhead Pharmaceuticals, Inc.

NameTitle
Dr. Christopher R. Anzalone Ph.D.
Chairman, CEO & President
Mr. Patrick O'Brien J.D., PharmD
COO, General Counsel & Secretary
Dr. James C. Hamilton M.D., MBA
Chief Medical Officer and Head of R&D
Dr. Mark M. Davis Ph.D.
Founder and Founder & Director of Insert Therapeutics Inc & Calando
Mr. Daniel J. Apel
Chief Financial Officer
Dr. Vincent Anzalone CFA
Head of Investor Relations & VP
Mr. Howard Lovy
Director of Communications
Dr. Bruce D. Given M.D.
Chief Medical Scientist
Dr. Mark Seefeld
Head of Toxicology & VP
Aaron Tan
Head of Tax

Important FAQs about investing in ARWR Stock from India :

What is Arrowhead Pharmaceuticals share price today?

Arrowhead Pharmaceuticals share price today is $21.32 as on at the close of the market. Arrowhead Pharmaceuticals share today touched a day high of $21.69 and a low of $20.80.

What is the 52 week high and 52 week low for Arrowhead Pharmaceuticals share?

Arrowhead Pharmaceuticals share touched a 52 week high of $27.34 and a 52 week low of $9.57. Arrowhead Pharmaceuticals stock price today i.e. is closed at $21.32, lower by 22.02% versus the 52 week high.

How to invest in Arrowhead Pharmaceuticals Stock (ARWR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Arrowhead Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arrowhead Pharmaceuticals Shares that will get you 0.0704 shares as per Arrowhead Pharmaceuticals share price of $21.32 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Arrowhead Pharmaceuticals Stock (ARWR) from India?

Indian investors can start investing in Arrowhead Pharmaceuticals (ARWR) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Arrowhead Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Arrowhead Pharmaceuticals share’s latest price of $21.32 as on August 23, 2025 at 1:29 AM IST, you will get 0.4690 shares of Arrowhead Pharmaceuticals. Learn more about fractional shares .

What are the returns that Arrowhead Pharmaceuticals has given to Indian investors in the last 5 years?

Arrowhead Pharmaceuticals stock has given -50.22% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?